Predicting in vivo drug interactions from in vitro drug discovery data

Nature Reviews Drug Discovery

Volumn 4, Issue 10, 2005, Pages 825-833

  Wienkers, Larry C ^a   Heath, Timothy G ^b  

^a AMGEN INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ASTEMIZOLE; BROMFENAC; BUFFER; CERIVASTATIN; CISAPRIDE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DICLOFENAC; GENERIC DRUG; MIBEFRADIL; NEFAZODONE; PHENYTOIN; QUINIDINE; SOLVENT; TERFENADINE; TOLBUTAMIDE;

ACCURACY; AREA UNDER THE CURVE; DATA ANALYSIS; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; ENZYME INACTIVATION; ENZYME KINETICS; ENZYME SUBSTRATE; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN FAMILY; QT PROLONGATION; REVIEW; SIDE EFFECT;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; METABOLIC DETOXICATION, DRUG; PREDICTIVE VALUE OF TESTS; TERMINOLOGY;

EID: 27644596457     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1851     Document Type: Review

References (104)

1. du Souich, P. In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can. J. Clin. Pharmacol. 8, 153-161 (2001).
2. Edwards, I. R. & Aronson, J. K. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 356, 1255-1259 (2000).
3. Sproule, B. A., Naranjo, C. A., Brenmer, K. E. & Hassan, P. C. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin. Pharmacokinet. 33, 454-471 (1997).
4. Saito, M., Hirata-Koizumi, M., Urano, T., Miyake, S. & Hasegawa, R. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J. Clin. Pharm. Ther. 30, 21-37 (2005).
5. Patsalos, P. N. & Perucca, E. Clinically important drug interactions in epilepsy: General features and interactions between antiepileptic drugs. Lancet Neurol. 2, 347-356 (2003).
6. Lazarou, J., Pomeranz, B. H. & Corey, P. N. Inddence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
7. Friedman, M. A. et al. The safety of newly approved medicines: Do recent market removals mean there is a problem? JAMA 281, 1728-1734 (1999).
8. Lasser, K. E. et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287, 2215-2220 (2002).
9. Williams, J. A. et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32, 1201-1208 (2004).
10. Hollenberg, P. F. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab. Rev. 34, 17-35 (2002).
11. Guengerich, F. P. Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol. 43, 7-35 (1997).
12. Porter, T. D. & Coon, M. J. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J. Biol. Chem. 266, 13469-13472 (1991).
13. Newton, D. J., Wang, R. W. and Lu, A. Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
14. Hutzler, J. M., Walker, G. S. & Wienkers, L. C. Inhibition of cytochrome P450 2D6: Structure-activity studies using a series of quinidine and quinine analogues. Chem. Res. Toxicol. 16, 450-459 (2003).
15. Guengerich, F. P., Muller-Enoch, D. & Blair, I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30, 287-295 (1986).
16. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry, Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro [online], (April 1997).
17. Bjornsson, T. D. et al. Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Reseach (CDER). The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31, 815-832 (2003).
18. Smith, D. A. & van de Waterbeemd, H. Pharmacokinetics and metabolism in early drug discovery. Curr. Opin. Chem. Biol., 3, 373-378 (1999).
19. Lin, J. H. & Lu, A. Y. H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49, 403-449 (1997).
20. Hutzler, M., Messing, D. M. & Wienkers, L. C. Predicting drug-drug interactions in drug discovery: Where are we now and where are we going? Curr. Opin. Drug Discov. Devel. 8, 51-58 (2005).
21. Ito, K., Ogihara, K., Kanamitsu, S. & Itoh, T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab. Dispos. 31, 945-954 (2003).
22. Donato, M. T. & Castell, J. V. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: Focus on in vitro studies. Clin. Pharmacokinet. 42, 153-178 (2003).
23. Wynalda, M. A. & Wienkers, L. C. Assessment of potential interactions between dopamine receptor agonists and vaious human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab. Dispos. 25, 1211-1214 (1997).
24. Moody, G. C., Griffin, S. J., Mather, A. N., McGinnity, D. F. & Riley, R. J. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica 29, 53-75 (1999).
25. Crespi, C. L. & Stresser, D. M. Fluorometric screening for metabolism-based drug-drug interactions. J. Pharmacol. Toxicol. Methods 44, 325-331 (2000).
26. Chauret, N. et al. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe. Anal. Biochem. 276, 215-226 (1999).
27. Cohen, L. H., Remley, M. J., Raunig, D. & Vaz, A. D. In vitro drug interactions of cytochrome P450: An evaluation of fluorogenic to conventional substrates. Drug Metab. Dispos. 31, 1005-1015 (2003).
28. Janiszewski, J. S. et al. A high-capacity LC/MS system for the bioanalysis of samples generated from plate-based metabolic screening. Anal. Chem. 73, 1495-1501 (2001).
29. Ayrton, J. et al. Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. Rapid Commun. Mass Spectrom. 12, 217-224 (1998).
30. Walsky, R. L. & Obach, R. S. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 32, 647-660 (2004).
31. Dierks, E. A. et al. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos. 29, 23-29 (2001).
32. Zhou, H., Tong, Z. & McLeod, J. F. 'Cocktail' approaches and strategies in drug development: Valuable tool or flawed science? J. Clin. Pharmacol. 44, 120-134 (2004).
33. Kunze, K. L., Wienkers, L. C., Thummel, K. E. & Trager, W. F. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab. Dispos. 24, 414-421 (1996).
34. Yao, C. et al. Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin. Pharmacol. Ther. 70, 415-424 (2001).
35. Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 (1973).
36. Gao, F. et al. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6 and CYP3A4 in vitro using a single point IC50. J. Biomol. Screen. 7, 373-382 (2002).
37. Yao, C. & Levy, R. H. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J. Pharm. Sci. 91, 1923-1935 (2002).
38. Neal, J. M., Kunze, K. L., Levy, R. H., O'Reilly, R. A. & Trager, W. F. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab. Dispos. 31, 1043-1048 (2003).
39. Kato, M., Tachibana, T., Ito, K. & Sugiyama, Y. Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. Drug Metab. Pharmacokinet. 18, 121-127 (2003).
40. Rane, A., Wilkinson, G. R. & Shand, D. G. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200, 420-424 (1977).
41. Bertz, R. J. & Granneman, G. R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32, 210-258 (1997).
42. Tyson, C. A. & Sugiyama, Y. Prediction of in vivo drug metabolism in human liver from in vitro metabolism data. Pharmacol. Ther. 73, 147-171 (1997).
43. Rowland, M. & Martin, S. B. Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm. 1, 553-567 (1973).
44. Thummel, K. E. & Wilkinson, G. R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
45. Fleishaker, J. C., Pearson, P. G., Wienkers, L. C., Pearson, L. K. & Peters, G. R. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J. Pharmacol. Exp. Ther. 277, 991-998 (1996).
46. Wienkers, L. C., Steenwyk, R. C., Sanders, P. E. & Pearson, P. G. Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J. Pharmacol. Exp. Ther. 277, 982-990 (1996).
47. Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y. & Sugiyama, Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38, 461-499 (1998).
48. 50 and inhibitor concentration. Curr. Drug. Metab. 5, 147-156 (2004).
49. Venkatakrishnan, K., von Moltke, L. L., Obach, R. S. & Greenblatt, D. J. Drug metabolism and drug interactions: Application and clinical value of in vitro models. Curr. Drug. Metab. 4, 423-459 (2003).
50. Lin, J. H. Sense and nonsense in the prediction of drug-drug interactions. Curr. Drug. Metab. 1, 305-331 (2000).
51. Obach, R. S. Importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions and implications for in vivo correlations. Drug Metab. Dispos. 24, 1047-1049 (1996).
52. Wienkers, L. C. Factors confounding the successful extrapolation of in vitro CYP3A inhibition information to the in vivo condition. Eur. J. Pharm. Sci. 15, 239-242 (2002).
53. Margolis, J. M. & Obach, R. S. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab. Dispos. 31, 606-611 (2003).
54. m values: Implications for clinical correlation. J. Pharmacol. Exp. Ther. 282, 391-396 (1997).
55. Gemzik, B., Halvorson, M. R. & Parkinson, A. Pronounced and differential effects of ionic strength and pH on testosterone oxidation by membrane-bound and purified forms of rat liver microsomal cytochrome P-450. J. Steroid Biochem. 35, 429-440 (1990).
56. 2+). Drug Metab. Dispos. 28, 1198-1201 (2000).
57. Hutzler, J. M., Powers, F. J., Wynalda, M. A. & Wienkers, L. C. Effect of carbonate anion on cytochrome P450 2D6-mediated metabolism in vitro: the potential role of multiple oxygenating species. Arch. Biochem. Biophys. 417, 165-175 (2003).
58. Nishimura, Y., Kurata, N., Iwase, M., Li, H. & Yasuhara, H. The effects of organic solvents on trimethadione N-demethylation in rats. Res. Commun. Mol. Pathol. Pharmacol. 104, 229-239 (1999).
59. Hickman, D., Wang, J. P., Wang, Y. & Unadkat, J. D. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab. Dispos. 26, 207-215 (1998).
60. Siebert, G. A., Hung, D. Y., Chang, P. & Roberts, M. S. Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J. Pharmacol. Exp. Ther. 308, 228-235 (2004).
61. Muller-Enoch, D. Investigations on the role of cytochrome b5 and divalent cations in the maximal nifedipine oxidase activity of human liver. Arzneimittelforschung 49, 470-475 (1999).
62. 5 directly induces positive cooperativity. Arch. Biochem. Biophys. 438, 21-28 (2005).
63. Kim, K. H., Ahn, T. & Yun, C. H. Membrane properties induced by anionic phospholipids and phosphatidylethanolamine are critical for the membrane binding and catalytic activity of human cytochrome P450 3A4. Biochemistry 42, 15377-15387 (2003).
64. Silverman, R. B. Mechanism-based enzyme inactivators. Methods Enzymol. 249, 240-283 (1995).
65. Kent, U. M., Juschyshyn, M. I. & Hollenberg, P. F. Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr. Drug. Metab. 2, 215-243 (2001).
66. Woodcroft, K. J., Webb, C. D., Yao, M., Weedon, A. C. & Bend, J. R. Metabolism of the cytochrome P450 mechanism-based inhibitor N-benzyl-1-aminobenzotriazole to products that covalently bind with protein in guinea pig liver and lung microsomes: Comparative study with 1-aminobenzotriazole. Chem. Res. Toxicol. 10, 589-599 (1997).
67. Mayhew, B. S., Jones, D. R. & Hall, S. D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28, 1031-1037 (2000).
68. Strobel, S. M. et al. Identification of selective mechanism-based inactivators of cytochromes P-450 2B4 and 2B5, and determination of the molecular basis for differential susceptibility. J. Pharmacol. Exp. Ther. 290, 445-451 (1999).
69. Kunze, K. L. & Trager, W. F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656 (1993).
70. Regal, K. A., Schrag, M. L., Kent, U. M., Wienkers, L. C. & Hollenberg, P. F. Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: Verification of apo-P450 adduction by electrospray ion trap mass spectrometry. Chem. Res. Toxicol. 13, 262-270 (2000).
71. Hutzler, J. M., Steenwyk, R. C., Smith, E. B., Walker, G. S. & Wienkers, L. C. Mechanism-based inactivation of cytochrome P450 2D6 by
72. Blobaum, A. L., Kent, U. M., Alworth, W. L. & Hollenberg, P. F. Novel reversible inactivation of cytochrome P450 2E1 T303A by tert-butyl acetylene: The role of threonine 303 in proton delivery to the active site of cytochrome P450 2E1. J. Pharmacol. Exp. Ther. 310, 281-290 (2004).
73. Schrag, M. L. & Wienkers, L. C. Covalent alteration of the CYP3A4 active site: Evidence for multiple substrate binding domains. Arch. Biochem. Biophys. 391, 49-55 (2001).
74. Yano, J. K. et al. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J. Biol. Chem. 279, 38091-38094 (2004).
75. Wester, M. R. et al. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution. J. Biol. Chem. 279, 35630-35637 (2004).
76. Tang, W. & Stearns, R. A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr. Drug. Metab. 2, 185-198 (2001).
77. Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M. & Lu, A. Y. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28, 360-366 (2001).
78. Korzekwa, K. R. et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple sites can simultaneously bind to cytochrome P450 active sites. Biochemistry 37, 4137-4147 (1998).
79. Dabrowski, M. J., Schrag, M. L., Wienkers, L. C. & Atkins, W. M. Pyrene. pyrene complexes at the active site of cytochrome P450 3A4: Evidence for a multiple substrate binding site. J. Am. Chem. Soc. 124, 11866-11867 (2002).
80. Tracy, T. S. Atypical enzyme kinetics: Their effect on in vitro-in vivo phamacokinetic predictions and drug interactions. Curr. Drug. Metab. 4, 341-346 (2003).
81. Houston, J. B. & Galetin, A. Modeling atypical CYP3A4 kinetics: principles and pragmatism. Arch. Biochem. Biophys. 433, 351-360 (2005).
82. Stresser, D. M. et al. Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates. Drug Metab. Dispos. 28, 1440-1448 (2000).
83. Shen, L., Fitzloff, J. F. & Cook, C. S. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab. Dispos. 32, 186-196 (2004).
84. Galetin, A., Clarke, S. E. & Houston, J. B. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab. Dispos. 31, 1108-1116 (2003).
85. Wang, R. W., Newton, D. J., Scheri, T. D. & Lu, A. Y. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab. Dispos. 25, 502-507 (1997).
86. Shou, M. et al. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: An example of the metabolism of diazepam and its derivatives. Biochem. J. 340, 845-853 (1999).
87. Davydov, D. R., Halpert, J. R., Renaud, J. P. & Hui Bon Hoa, G. Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. Biochem. Biophys. Res. Commun. 312, 121-130 (2003).
88. Ueng, Y. F., Kuwabara, T., Chun, Y. J. & Guengerich, F. P. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36, 370-381 (1997).
89. Kenworthy, K. E., Bloomer, J. C., Clarke, S. E. & Houston, J. B. CYP3A4 drug interactions: Correlation of ten in vitro probe substrates. Br. J. Clin. Pharmacol. 48, 716-727 (2001).
90. Shou, M. et al. Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug. Metab. 2, 17-36 (2001).
91. Schrag, M. L. & Wienkers, L. C. Triazolam substrate inhibition: Evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab. Dispos. 29, 70-75 (2001).
92. Hutzler, J. M., Wienkers, L. C., Wahlstrom, J. L., Carlson, T. J. & Tracy, T. S. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch. Biochem. Biophys. 410, 16-24 (2003).
93. Hutzler, J. M. et al. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur. J. Pharm. Sci. 14, 47-52 (2001).
94. Rodrigues, A. D. & Rushmore, T. H. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr. Drug. Metab. 3, 289-309 (2002).
95. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 286, 2270-2279 (2001).
96. Zanger, U. M., Raimundo, S. & Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-37 (2004).
97. Sachse, C., Brockmoller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
98. Furuya, H. et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5, 389-392 (1995).
99. Sullivan-Klose, T. H. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996).
100. Schwarz, U. I. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur. J. Clin. Investig. 33, 23-30 (2003).
101. Takahashi, H. & Echizen, H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40, 587-603 (2001).
102. Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F. & Korzekwa, K. R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4, 39-42 (1994).
103. Marks, B. D., Thompson, D. V., Goossens, T. A. & Trubetskoy, O. V. High-throughput screening assays for the assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 metabolism using fluorogenic Vivid substrates. J. Biomol. Screen. 9, 439-449 (2004).
104. Verstuyft, C. et al. A new, rapid and robust genotyping method for CYP2C9 and MDR1. Ann. Biol. Clin. (Paris) 61, 305-309 (2003).